Business Context and Reporting Period
This Form 8-K was filed by Eton Pharmaceuticals, Inc. on March 1, 2023. The report discloses a corporate governance event regarding the appointment of a new executive officer effective March 1, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the internal promotion of David Krempa to the position of Chief Business Officer. Previously, Mr. Krempa served as Senior Vice President, Business Development and Investor Relations.
Management Commentary and Compensation Details
- Compensation: Mr. Krempa will receive an annual salary of $385,000 and is eligible for an annual discretionary bonus determined by the board of directors.
- Equity: He participates in the Company's 2018 Equity Incentive Plan.
- Severance: In the event of termination without "cause" or resignation for "good reason," Mr. Krempa is entitled to six months of base salary.
- Change in Control: If termination occurs within twelve months of a change in control, all unvested stock options shall immediately vest.
- Employment Status: Employment is "at will" and may be terminated by the Company at any time.
Investor Verification Checklist
- Verify the exact vesting schedule and number of options granted to Mr. Krempa under the 2018 Equity Incentive Plan.
- Review the Company's recent cash position to assess the impact of the new executive salary on operating expenses.
- Confirm if this appointment signals a strategic shift in business development or investor relations priorities.